Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome (NCT07506551) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome
Austria24 participantsStarted 2023-07-06
Plain-language summary
Determination of proteins and their levels in the vitreous of eyes with or without pseudoexfoliation syndrome (PEX)
Who can participate
Age range21 Years – 105 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* PEX syndrome
* Macular pucker or macular hole and scheduled for vitrectomy
* Age 21 or older
* Written informed consent prior to surgery
Exclusion Criteria:
* Previous vitrectomy or intravitreal application of drugs
* Systemic anti-inflammatory drugs
* Pre- surgical topical anti-inflammatory drugs (NSAR, Steroids)
* Pre- surgical topical prostaglandins
* Diabetic retinopathy
* AMD
* PEX Syndrome only in the contralateral eye (the eye not scheduled for surgery)